-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KaDvfhE4qWOicrODtdu42ht33E11Wer7ti4faLinUj10lWxRz+zdkkq8CPf0aqTm U+/Xi9mKS9JIwuY4csf7fQ== 0001070081-09-000003.txt : 20091222 0001070081-09-000003.hdr.sgml : 20091222 20091222170635 ACCESSION NUMBER: 0001070081-09-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20091222 DATE AS OF CHANGE: 20091222 EFFECTIVENESS DATE: 20091222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-61608 FILM NUMBER: 091255808 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 D 1 primary_doc.xml X0603 D LIVE 0001070081 PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080-2449 9082227000 DELAWARE PTC THERAPEUTICS INC Corporation true Stuart W. Peltz c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Executive Officer Director Langdon L. Miller c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Executive Officer Mark E. Boulding c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Executive Officer William Baird, III c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Executive Officer Allan S. Jacobson c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Director Michael Schmertzler c/o Credit Suisse First Boston 11 Madison Avenue New York NY 10010 Director David P. Southwell c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Director Carl Goldfischer c/o Bay City Capital Fund III LP 750 Battery Street San Francisco CA 94111 Director Soren Carlsen c/o Novo A/S Krogshoejvej 41 Bagsvaerd G7 DK Director Michael Kranda c/o Vulcan Ventures, Inc. 505 Fifth Avenue, S., #900 Seattle WA 98104 Director Axel Bolte c/o HBM Partners AG Limmetquai 122, 8001 Zurich V8 CH Director Deepa Pakianathan c/o PTC Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080-2449 Director Biotechnology $25,000,001 - $100,000,000 06 false 2009-12-22 false true false 0 50300000 25150064 25149936 false 21 0 0 0 false PTC THERAPEUTICS, INC. /s/ Mark E. Boulding Mark E. Boulding Senior Vice President and General Counsel 2009-12-22 -----END PRIVACY-ENHANCED MESSAGE-----